DrugRepV|Encyclopedia for antivirals

Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_4790

Chemical Information
Antiviral agent ID DrugRepV_4790
Antiviral agent name 4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid
IUPAC Name 4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid
SMILES (canonical) OC(=O)C1=CC=C(Cl)C=C1C1=CC=C(O1)\C=C1/C(=O)N(N=C1C1=CC=CC=C1)C1=CC=C(F)C=C1
Molecular Formula C27H16ClFN2O4
Molecular Weight (g/mol) 486.88

InChl InChI=1S/C27H16ClFN2O4/c28-17-6-12-21(27(33)34)22(14-17)24-13-11-20(35-24)15-23-25(16-4-2-1-3-5-16)30-31(26(23)32)19-9-7-18(29)8-10-19/h1-15H,(H,33,34)/b23-15-
Structural Information

Clinical Information
Biological Information
Secondary Indication Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA
Secondary Indication (Approaches) Experimental
Secondary Indication (Methods) In-vitro
Secondary Indication (Drug concentration) 20.2 ± 0.3 μM
Secondary Indication (Change) Decrease
Secondary Indication (Type of Inhibition) IC50 [ 50 % ]
Reference Kumar V, Tan KP, Wang YM, Lin SW, Liang PH..Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors..Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. doi: 10.1016/j.bmc.2016.05.013. Epub 2016 May 12. PMID:27240464
Comment Docking studies show that a carboxylate present at either R¹ or R⁴ destabilizes the oxyanion hole in the 3CL^pro. Compounds 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop broad-spectrum antiviral agents.

Copyright © 2019. CSIR-Institute of Microbial Technology, Chandigarh, INDIA.

Chemical Information
Antiviral agent ID	DrugRepV_4790
Antiviral agent name	4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid
IUPAC Name	4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid
SMILES (canonical)	OC(=O)C1=CC=C(Cl)C=C1C1=CC=C(O1)\C=C1/C(=O)N(N=C1C1=CC=CC=C1)C1=CC=C(F)C=C1
Molecular Formula	C27H16ClFN2O4
Molecular Weight (g/mol)	486.88
InChl	InChI=1S/C27H16ClFN2O4/c28-17-6-12-21(27(33)34)22(14-17)24-13-11-20(35-24)15-23-25(16-4-2-1-3-5-16)30-31(26(23)32)19-9-7-18(29)8-10-19/h1-15H,(H,33,34)/b23-15-
Structural Information

Clinical Information
Biological Information
Secondary Indication	Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Drug concentration)	20.2 ± 0.3 μM
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC50 [ 50 % ]
Reference	Kumar V, Tan KP, Wang YM, Lin SW, Liang PH..Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors..Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. doi: 10.1016/j.bmc.2016.05.013. Epub 2016 May 12. PMID:27240464
Comment	Docking studies show that a carboxylate present at either R¹ or R⁴ destabilizes the oxyanion hole in the 3CL^pro. Compounds 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop broad-spectrum antiviral agents.